- ERS Genomics has signed a non-exclusive licensing agreement with Aurigene Pharmaceutical Services for access to its CRISPR/Cas9 patent portfolio.
- The agreement allows Aurigene to integrate genome editing capabilities into its drug discovery and development platforms for pharmaceutical and biotechnology clients.
ERS Genomics has entered into a non-exclusive licensing agreement with Aurigene Pharmaceutical Services Limited, providing the company access to ERS’ foundational CRISPR/Cas9 intellectual property portfolio.
Under the agreement, Aurigene will incorporate CRISPR/Cas9 genome editing technology into its discovery platforms to support pharmaceutical and biotechnology partners working across small molecule and biologics programs. The companies stated that the collaboration is intended to strengthen Aurigene’s target validation, disease model generation, and functional genomics capabilities.
According to ERS Genomics, CRISPR/Cas9 technology enables precise DNA modification and is increasingly used in drug discovery workflows, including cell line engineering and genomic research. The company added that access to foundational intellectual property is important for organizations seeking to deploy genome editing technologies across commercial and research applications.
“At Aurigene, we are constantly investing in technologies that bring value to our customers. Access to ERS’ foundational CRISPR/Cas9 intellectual property enables us to integrate cutting-edge gene editing capabilities into our discovery workflows.”
Akhil Ravi, Chief Executive Officer of Aurigene Pharmaceutical Services Limited
ERS Genomics stated that the agreement expands its global network of CRISPR licensees and supports broader adoption of genome editing technologies in drug discovery and development. Aurigene said the collaboration strengthens its integrated CRDMO platform and enhances services provided to global biopharmaceutical partners.
